Table 2 of
Andrieu-Soler, Mol Vis 2007;
Table 2. Quantification of rhodopsin immunostaining on untreated and treated rd1 flat-mount retinas
rd1 mice were treated (inontophoresis followed by intravitreal injection) at PN4, PN6, and PN8 (unless otherwise indicated) with a 500 μM of various oligonucleotides (ODNs). Other mice received no treatment (None) or were treated with vehicle (PBS). WTS (PN4) are data from mice treated only at PN4 (e.g., only one treatment total). WTS (PN4 and PN6) are data from mice treated at PN4 and PN6 (e.g., only two treatments total). At PN28, retinas were harvested, flat-mounted, and assayed for rhodopsin immunoreactivity using a fluorescently labeled secondary antibody. Fluorescence was quantified by using the luminosity feature of Adobe Photoshop to normalize the average brightness level per pixel of the tissue region to that of the background region in each flat-mount image. Data are mean of normalized fluorescence ±standard deviation. Sampling was number of retinas per group. Three separate treatments with WTS produced rhodopsin immunoreactivity significantly greater than other treatments (*p<0.001 by simple analysis of variance (ANOVA) with Student-Newman-Keuls post-hoc testing). All other treatments were statistically indistinguishable from PBS treatment (p>0.05).
Number Standard of Treatment Tissue Fl/Bkgd Fl deviation retinas --------------- ----------------- --------- ------- None 1.36 0.09 6 PBS 1.71 0.17 6 WTS 2.57* 0.44 6 WTSscr25 1.67 0.11 6 WTSscr7 1.63 0.11 6 WTS (PN4) 1.40 0.17 4 WTS (PN4 and PN6) 1.86 0.12 4